コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 of liver dysfunction (Child-Turcotte-Pugh or Model for End-Stage Liver Disease scores).
2 etween different age groups who had the same Model for End-Stage Liver Disease score.
3 alization, age, sex, type of transplant, and model for end-stage liver disease score.
4 verity parameters including age, gender, and Model for End-Stage Liver Disease score.
5 isoforms correlated with both Child-Pugh and Model for End-Stage Liver Disease scores.
6 bin time/international normalized ratio, and Model for End-Stage Liver Disease scores.
7 monia, levels of inflammatory cytokines, and model for end-stage-liver disease scores.
8 idates (mean age, 56 years; 35% female; mean Model for End-stage Liver Disease score, 10.8; range, 6-
9 -8.4), average Child score 8.3 (+/-1.3), and Model for End-Stage Liver Disease score 11.7 (+/-3.9).
10 12 years; mean Child Pugh, 7 +/- 3; and mean model for end-stage liver disease score, 13 +/- 6) compl
12 8%, P</=0.05) and to have a higher mean (SD) model for end-stage liver disease score (24 [11] vs. 22
13 ithout DC, patients requiring DC had greater Model for End-stage Liver Disease scores (33 vs 27; P <
14 es decreased after the implementation of the model for end-stage liver disease score and a concomitan
16 nger time interval from LRT to LT, and lower model for end-stage liver disease score and maximum tumo
17 nfection after LT was associated with higher model for end-stage liver disease scores and receiving a
18 ent success may ultimately hinge on regional model for end-stage liver disease scores and waiting tim
19 e, body mass index, hepatitis C virus (HCV), model for end-stage liver disease score, and acute rejec
20 hepatorenal syndrome, dialysis requirement, model for end-stage liver disease score, and alcoholic l
21 ite adjustment for age, sex, race/ethnicity, Model for End-Stage Liver Disease score, and liver trans
22 recipient and donor length of stay, greater Model for End-stage Liver Disease score, and longer warm
23 ith donor acceptance were younger age, lower Model for End-stage Liver Disease score, and shorter tim
24 no difference regarding cold ischemia time, model for end-stage liver disease score, and steatosis.
27 nts with ALD had a significantly higher mean Model for End-Stage Liver Disease score at time of waitl
29 and transplantation network so that patient model for end-stage liver disease scores at transplant i
30 the presence of cirrhosis, the dichotomized model for end-stage liver disease score below and above
31 ither group had changes in ammonia levels or model for end-stage-liver disease scores, but patients i
32 randomization, controlling for age, gender, Model for End-Stage Liver Disease score, Child-Pugh scor
33 gical response rates, LT costs, and baseline Model for End-Stage Liver Disease score (DCC analysis on
34 fit, resulting in transplantation at a lower model for end-stage liver disease score, decreased death
35 weeks was maintained at 6 months; Child and Model for End-Stage Liver Disease scores did not change.
36 e unit stay more than 3 days (OR 10.23), and Model for End-Stage Liver Disease score greater than 21
37 ncluded recipient age greater than 55 years, Model for End-Stage Liver Disease score greater than 27,
38 E infection were acquisition of CRE post-LT, Model for End-Stage Liver Disease score greater than 32,
39 with moderate to severe alcoholic hepatitis (Model for End-Stage Liver Disease score > or = 15) were
42 + 0.9858 [blood urea nitrogen >27] + 0.4574 [Model for End-Stage Liver Disease score >21] + 1.1625 [i
43 e heavy weighting of serum creatinine in the model for end-stage liver disease score has significantl
44 llness-related corticosteroid insufficiency, Model for End-Stage Liver Disease score, hypovolemic sho
47 three groups were most noticeable for lower model for end-stage liver disease scores in LD recipient
48 n for HE, as well as Child-Turcotte-Pugh and model for end-stage liver disease scores, in patients wi
49 eral preoperative factors (age of recipient, model for end-stage liver disease score, indication for
50 ed with a lower 12-month graft survival than Model for End-Stage Liver Disease score <15 (P=0.02).
51 syndrome (45.1% versus 14.8%), and had lower model for end-stage liver disease scores (median 9 versu
52 e analysis, CDI was associated with having a model for end-stage liver disease score of 20 or greater
54 ect of ACLF, defined as an acute rise in the Model for End-Stage Liver Disease score of more than 5 w
55 offers of a high-quality liver when they had Model for End-stage Liver Disease scores of 15 or greate
57 ad higher liver stiffness (P < 0.001), worse Model for End-Stage Liver Disease score (P < 0.001), mor
58 patients had significantly lower laboratory model for end-stage liver disease scores, pretransplant
59 light-EEG correlated significantly with the Model for End-Stage Liver Disease score (r = -0.39, P <
60 tudy groups did not differ in recipient age, model for end-stage liver disease score, steatosis, and
61 er from comorbidities unaccounted for by the model for end-stage liver disease scoring system and may
64 ipients was 50.2 +/- 8.5 years, and the mean model for end-stage liver disease score was 12.2 +/- 4.6
70 the control group, from baseline (P = .001); Model for End Stage Liver Disease scores were reduced by
71 ovement in renal function and lower baseline Model for End-Stage Liver Disease score were associated
72 iable analysis, only the Lille model and the Model for End-Stage Liver Disease score were independent
74 variables needed to calculate Child-Pugh and Model for End-Stage Liver Disease scores were recorded.
75 he factors used in Donor Risk Index with the model for end-stage liver disease score yields an AUC-RO
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。